Loading...
•
Dec 31, 2021
Atai Q4 2021 Earnings Report
Atai Life Sciences reported financial results for Q4 2021 and provided business updates.
Key Takeaways
Atai Life Sciences ended 2021 with a strong cash position of $362 million. The company anticipates at least 14 drug development and enabling technology catalysts over the next two years. They are focused on rapid acting intervention, ongoing digital support and a biomarker-driven precision mental health.
atai increased its holdings in COMPASS Pathways to 22.8% in Q4 2021.
In December 2021, the FDA gave Investigational New Drug (IND) clearance for the development of PCN-101 for the treatment of TRD.
atai announced positive biomarker data from the Phase 2a proof-of-mechanism study of RL-007 in CIAS patients in December of last year.
atai ended the year with a strong cash position of $362 million which it anticipates will be sufficient to provide a cash runway of approximately two years.
Atai
Atai
Forward Guidance
The Company anticipates at least 14 drug development and enabling technology catalysts over the next two years.
Positive Outlook
- Phase 2a proof-of-concept topline data readout with PCN-101 for TRD
- Results from the Phase 1 relative bioavailability study with PCN-101 designed to bridge between the current intravenous formulation to a subcutaneous formulation to support at-home use.
- Data from the Phase 1 element of a combined Phase 1/2 trial of DMX-1002 by the end of 2022
- Topline data from a Phase 1 trial with GRX-917 by mid of this year.
- Topline results for KUR-101 study later this year.